These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3424407)

  • 1. Lack of apparent effect of assay methodology on the pharmacokinetics of digoxin.
    Blum RA; DeVito JM; Pleasants RA; Crass RE; Gadsden RH; Leman RB
    Ther Drug Monit; 1987 Dec; 9(4):416-21. PubMed ID: 3424407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interference of digoxin-like immunoreactive substances with three digoxin immunoassays in patients with various degrees of renal function.
    Pleasants RA; Gadsden RH; McCormack JP; Piveral K; Sawyer WT
    Clin Pharm; 1986 Oct; 5(10):810-6. PubMed ID: 3780148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring endogenous digoxin-like substance and exogenous digoxin in the serum of low-birth-weight infants.
    Ng PK; LeGatt D; Coates J; Collins-Nakai RL
    Am J Hosp Pharm; 1985 Sep; 42(9):1977-9. PubMed ID: 3901741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digoxin-like immunoreactive substance: monoclonal and polyclonal RIA and FPIA compared.
    Mojaverian P; Green PJ; Jhangiania RK; Chase GD
    J Pharm Biomed Anal; 1989; 7(5):585-92. PubMed ID: 2490762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [False results of measuring digoxin levels in patients with renal failure. Comparison of the RIA--FPIA methods].
    Jankowski A; Karwowski J; Marzec A; Kretowicz W; Nartowicz E
    Kardiol Pol; 1990 Feb; 33(2):116-21. PubMed ID: 2277482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. False-positive serum digoxin concentrations determined by three digoxin assays in patients with liver disease.
    Frisolone J; Sylvia LM; Gelwan J; Pal S; Pellechia C
    Clin Pharm; 1988 Jun; 7(6):444-9. PubMed ID: 3402179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variances in pharmacokinetic parameters due to assay methods for beta-methyldigoxin.
    Goto M; Suzuki A; Terashima T; Johno I; Kitazawa S
    J Pharmacobiodyn; 1987 May; 10(5):209-14. PubMed ID: 3305859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive performance study of two digoxin assays in subjects with various degrees of renal function.
    Spinler SA; Al-Jazairi AS; Cheng JW; Kapoor S; Kobrin S; Shaw L
    Ther Drug Monit; 2000 Dec; 22(6):729-36. PubMed ID: 11128242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
    Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
    Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intercomparison of seven radioimmunoassay kits and a fluorescence polarization immunoassay kit for digoxin.
    Erickson KA; Green PJ
    Clin Chem; 1984 Jul; 30(7):1225-7. PubMed ID: 6733904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interference between eplerenone and digoxin in fluorescence polarization immunoassay, microparticle enzyme immunoassay, and affinity column-mediated immunoassay.
    Yamada T; Suzuki K; Iguchi K; Kanada Y; Kato R; Ijiri Y; Nishihara M; Murakami S; Hayashi T; Tamai H; Tanaka K
    Ther Drug Monit; 2010 Dec; 32(6):774-7. PubMed ID: 20625353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays.
    Pleasants RA; Williams DM; Porter RS; Gadsden RH
    Ther Drug Monit; 1989; 11(2):200-4. PubMed ID: 2655203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of protein concentration on the determination of digoxin in serum by fluorescence polarization immunoassay.
    Porter WH; Haver VM; Bush BA
    Clin Chem; 1984 Nov; 30(11):1826-9. PubMed ID: 6207958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digoxin-like immunoreactive substance in renal transplant patients.
    Schrader BJ; Maddux MS; Veremis SA; Mozes MF; Maturen A; Bauman JL
    J Clin Pharmacol; 1991 Dec; 31(12):1126-31. PubMed ID: 1662232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposable-column radioimmunoassay for serum digoxin with less interference from metabolites and endogenous digitalis-like factors.
    Longerich L; Vasdev S; Johnson E; Gault MH
    Clin Chem; 1988 Nov; 34(11):2211-6. PubMed ID: 2846204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous digoxin-like immunoreactive factors (DLIF) as measured by the CEDIA digoxin assay and a fluorescence polarization immunoassay.
    Schlebusch H; Jarausch J; Domke I
    Wien Klin Wochenschr Suppl; 1992; 191():59-66. PubMed ID: 1509757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of high pressure liquid chromatography and fluorescence polarization immunoassay to assess quinidine pharmacokinetics.
    Bottorff MB; Lalonde RL; Straughn AB
    Biopharm Drug Dispos; 1987; 8(3):213-21. PubMed ID: 3297181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of troglitazone on steady-state pharmacokinetics of digoxin.
    Loi CM; Knowlton PW; Stern R; Randinitis EJ; Vassos AB; Koup JR; Sedman AJ
    J Clin Pharmacol; 1998 Feb; 38(2):178-83. PubMed ID: 9549650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interference from digitoxin-like immunoreactive factors reduced in a new monoclonal chemiluminescent digitoxin assay.
    Datta P; Dasgupta A
    Ther Drug Monit; 1998 Dec; 20(6):663-8. PubMed ID: 9853984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of the Abbott TDx fluorescence polarization immunoassay analyzer.
    Oeltgen PR; Shank WA; Blouin RA; Clark T
    Ther Drug Monit; 1984; 6(3):360-7. PubMed ID: 6390799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.